The DEA (Drug Enforcement Administration, the US agency that controls which drugs researchers can access) is very unlikely to announce any expansion of how much psilocybin researchers are allowed to use or produce before the end of 2026. Psilocybin is still a Schedule I drug — the most restricted category — and the DEA rarely acts on its own without enormous outside pressure. A recent high-profile death connected to psychedelic therapy has made the political environment even more cautious.
Schedule I posture holds; even research-supply expansions require pressure DEA won't volunteer amid a highly publicized death.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →